Section Arrow
VRTX.NASDAQ
- Vertex Pharmaceuticals
Quotes are at least 15-min delayed:2024/10/31 18:47 EDT
Last
 476.12
+1.04 (+0.22%)
Day High 
477.695 
Prev. Close
475.08 
1-M High
499.09 
Volume 
1.38M 
Bid
475.91
Ask
475.74
Day Low
468.98 
Open
471.58 
1-M Low
447.7 
Market Cap 
122.62B 
Currency USD 
P/E 30.95 
%Yield -- 
10-SMA 477.62 
20-SMA 473.74 
50-SMA 474.62 
52-W High 510.635 
52-W Low 341.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.98/18.42
Enterprise Value
123.34B
Balance Sheet
Book Value Per Share
57.24
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
9.87B
Operating Revenue Per Share
24.85
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 18:47 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.